Hims & Hers Health, Inc.
HIMSHims & Hers Health, Inc. is a telehealth company that offers a range of healthcare and wellness products and services. It provides virtual consultations, prescription medications, and over-the-counter wellness products across categories such as mental health, dermatology, sexual health, and primary care, aiming to improve access and convenience in healthcare delivery.
Company News
Lowey Dannenberg, P.C. announces an investigation into Hims & Hers Health, Inc. for allegedly collecting and sharing subscribers' sensitive health information with third parties without proper consent, in violation of privacy policies and federal/state privacy laws. Eligible U.S. residents may recover up to $10,000 in compensation through binding...
Hims & Hers (HIMS) has surged 45% in the past month and 160% year-to-date, but technical indicators suggest a correction is due. However, a major catalyst looms: employers are planning to drop GLP-1 drug coverage in 2027, which should drive patients to direct-to-consumer telehealth providers like Hims & Hers. The stock's RSI is overbought at 70.8...
The article examines whether Hims & Hers Health (HIMS) represents an undervalued investment opportunity. The stock is noted as one of the most volatile in the market, with recent price movements following earnings announcements. The article suggests the healthcare industry is ripe for disruption, positioning the company within this context.
Hims & Hers is pursuing aggressive international expansion through its $1.15 billion acquisition of Australian telehealth platform Eucalyptus, funded by $350 million in zero-coupon convertible debt. However, the company faces headwinds following a significant earnings miss in May, with shares down 18% since the earnings call and one-year performa...
Hims & Hers announced a $350 million convertible debt offering to fund growth plans. The debt will either be converted to stock, diluting shareholders, or require cash repayment, adding significant risk to the business. The company has limited time to prove it remains a growth company to the market.
